Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy

BACKGROUND: Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiteni, Frédéric, Jary, Marine, Monnien, Franck, Nguyen, Thierry, Beohou, Eric, Demarchi, Martin, Dobi, Erion, Fein, Francine, Cleau, Denis, Fratté, Serge, Nerich, Virginie, Bonnetain, Franck, Pivot, Xavier, Borg, Christophe, Kim, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236575/
https://www.ncbi.nlm.nih.gov/pubmed/25117717
http://dx.doi.org/10.1186/1471-230X-14-143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236575/
https://www.ncbi.nlm.nih.gov/pubmed/25117717
http://dx.doi.org/10.1186/1471-230X-14-143

Ejemplares similares